How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

297 results for

adhd Bupropion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Bupropion in children with attention deficit disorder. (Abstract)

Bupropion in children with attention deficit disorder. 2513592 1990 02 08 2013 11 21 0048-5764 25 2 1989 Psychopharmacology bulletin Psychopharmacol Bull Bupropion in children with attention deficit disorder. 198-201 Casat C D CD Pleasants D Z DZ Schroeder D H DH Parler D W DW eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Psychopharmacol Bull 0101123 0048-5764 0 Propiophenones 01ZG3TPX31 Bupropion IM Attention (...) Deficit Disorder with Hyperactivity drug therapy psychology Bupropion Child Double-Blind Method Humans Propiophenones therapeutic use Psychiatric Status Rating Scales Randomized Controlled Trials as Topic 1989 1 1 1989 1 1 0 1 1989 1 1 0 0 ppublish 2513592

1990 Psychopharmacology Bulletin Controlled trial quality: uncertain

282. Bupropion effects in attention deficit and conduct disorders. (Abstract)

Bupropion effects in attention deficit and conduct disorders. Children with Attention Deficit and/or Conduct Disorders were treated with bupropion, a new antidepressant, to determine its clinical, cognitive, and EEG effects. Seventeen male patients (age range 7 to 13.4 years; mean 10.4) participated in an open clinical trial consisting of a baseline placebo period (4 weeks), bupropion therapy (8 weeks), and post-drug placebo (2 weeks). Evaluations included clinical assessments, parents (...) , teachers, and self-ratings; cognitive tests and blood level measurements of bupropion. Fifteen patients received a daily maximum of 150 mg, one received 100 mg and one 50 mg. Clinical global improvement with bupropion therapy was marked in 5 patients, moderate in 7, mild in 2, and none in 3. The Children's Psychiatric Rating Scale indicated improvements of hyperactivity, withdrawal, anxiety, hostility/uncooperativeness, sleep disorder, antisocial behaviour, neuroticism, depression and eating

1986 Canadian journal of psychiatry. Revue canadienne de psychiatrie

283. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. (Abstract)

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. To evaluate the effects of medications used in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD) on blood pressure and pulse.Subjects were those with DSM-III-R-/DSM-IV-diagnosed ADHD enrolled in placebo-controlled studies of 5 different medications for ADHD. Cardiovascular data from these studies of both stimulants (methylphenidate, amphetamine (...) compounds, pemoline) and nonstimulants (bupropion, desipramine) were reanalyzed for baseline-to-endpoint active-treatment or placebo effects on blood pressure and heart rate.There were 125 subjects with a mean +/- SD age of 39 +/- 9 years. In general, active drug treatment for ADHD compared to baseline was associated with several statistically significant changes in systolic blood pressure (bupropion: +5.9 mm Hg, p < .05 by paired t test; amphetamine: +5.4 mm Hg, p < .05), diastolic blood pressure

2005 Journal of Clinical Psychiatry Controlled trial quality: uncertain

284. Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

of methylphenidate in improving cognitive and behavioral outcomes in children with both ASD and ADHD. Condition or disease Intervention/treatment Phase Autism Attention Deficit Disorder With Hyperactivity Drug: Methylphenidate-extended release Drug: Methylphenidate-immediate release Other: Placebo Phase 2 Phase 3 Detailed Description: Attention Deficit Hyperactivity Disorder (ADHD) is a major comorbid psychiatric disorder in children with Autism Spectrum Disorders (ASD) that significantly undermines behavioral (...) Center, Houston ClinicalTrials.gov Identifier: Other Study ID Numbers: DDTR B2-NDA First Posted: September 15, 2005 Results First Posted: May 7, 2013 Last Update Posted: May 9, 2013 Last Verified: May 2013 Additional relevant MeSH terms: Layout table for MeSH terms Autistic Disorder Attention Deficit Disorder with Hyperactivity Hyperkinesis Autism Spectrum Disorder Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders Attention Deficit and Disruptive Behavior Disorders

2005 Clinical Trials

285. A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Study ID Numbers: 2003-p-000037 First Posted: September 16, 2005 Last Update Posted: June 27, 2013 Last Verified: June 2013 Keywords provided by Joseph Biederman, MD, Massachusetts General Hospital: ADHD Adults Concerta Double-Blind Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Methylphenidate Central Nervous System Stimulants Physiological (...) : June 27, 2013 Sponsor: Massachusetts General Hospital Collaborator: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Information provided by (Responsible Party): Joseph Biederman, MD, Massachusetts General Hospital Study Details Study Description Go to Brief Summary: This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD

2005 Clinical Trials

286. Attention Deficit Hyperactivity Disorder

and based on research evidence, UK and European Guidelines. You may find the article more useful, or one of our other . In this article In This Article Attention Deficit Hyperactivity Disorder In this article Synonyms: hyperkinetic disorder, attention deficit disorder (ADD) Attention deficit hyperactivity disorder (ADHD) is a persistent pattern of inattention and/or hyperactivity and impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level (...) Attention Deficit Hyperactivity Disorder ADD or Attention Defecit and Hyperactivity Disorder - Patient | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Attention Deficit Hyperactivity Disorder Authored by , Reviewed by | Last edited 16 Apr 2014 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors

2008 Mentor

287. Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD)

, 2009 Last Verified: January 2009 Keywords provided by University Hospital Freiburg: ADHD Attention Deficit Disorder Attention Deficit an Disruptive Behavior Disorders Children Central Nervous System Stimulants Methylphenidate Pharmacokinetics Area Under Curve Therapeutic Equivalency Psychopharmacology Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders (...) Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD) Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2008 Clinical Trials

288. Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)

Verified: December 2013 Keywords provided by Joseph Biederman, MD, Massachusetts General Hospital: ADHD NOS Adults Strattera (atomoxetine) Open-Label Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms (...) Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2005 Clinical Trials

289. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. (Abstract)

Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Data remain limited on treatment strategies for adults with attention-deficit/hyperactivity disorder (ADHD). This study evaluated the efficacy and safety of an extended-release, once-daily formulation of bupropion (XL) in the treatment of adults with ADHD.This multisite, placebo-controlled, 8-week prospective trial evaluated 162 adult patients diagnosed with ADHD (combined (...) and inattentive types). Subjects were treated with up to 450 mg/day of bupropion XL. The primary efficacy endpoint was the proportion of ADHD responders (defined as at least a 30% reduction in the investigator-rated ADHD Rating Scale score) at week 8 (last observation carried forward [LOCF]).Bupropion XL responders (53%) exceeded placebo responders (31%) (p =.004 at week 8) with a significantly greater proportion of bupropion XL responders as early as week 2 (p = .01). Treatment effect size calculated

2005 Biological psychiatry Controlled trial quality: uncertain

290. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. (Abstract)

A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. Since attention-deficit/hyperactivity disorder (ADHD) is a well-documented risk factor for smoking and bupropion has been shown to be effective for smoking cessation, we tested the efficacy of bupropion as a prophylactic agent for the prevention of smoking in children and adolescents with ADHD.We conducted a longitudinal (...) , randomized, double-blind, placebo-controlled, parallel-group study of bupropion at a large, urban, outpatient medical center. Recruitment began in April 1999, and the last subject was followed until September 2004. Patients were nonsmoking youth, of both sexes, between 9 and 18 years of age, with DSM-IV ADHD. After random assignment to either bupropion or placebo, subjects were assessed weekly for 8 weeks, biweekly for 4 weeks, and monthly thereafter for up to 6.5 years (mean 12 months). Also, patients

2007 Journal of Clinical Psychiatry Controlled trial quality: predicted high

291. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. (Abstract)

Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. Few studies exist on pharmacological interventions for adolescents with substance use disorders (SUD). To this end, we evaluated the response of bupropion hydrochloride sustained release (SR) in SUD adolescents with comorbid psychopathology (both attention-deficit/ hyperactivity disorder (ADHD) and a mood disorder).Fourteen adolescent outpatients were (...) ). No significant adverse events were noted during the follow-up period.These naturalistic data suggest that bupropion is well tolerated and may be an effective medication for the treatment of substance abusing adolescents with comorbid mood disorders and ADHD.

2005 Journal of Child and Adolescent Psychopharmacology

292. Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients

Psychiatric Institute Collaborator: National Institute on Drug Abuse (NIDA) Information provided by (Responsible Party): Frances R Levin, New York State Psychiatric Institute Study Details Study Description Go to Brief Summary: The purpose of this study is to treat Adult Attention Deficit Hyperactivity Disorder (ADHD) in methadone patients. Condition or disease Intervention/treatment Phase ADHD Opioid-Related Disorders Cocaine Dependence Drug: Methylphenidate Drug: Bupropion Other: Placebo Phase 2 Phase 3 (...) -Related Disorders Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Substance-Related Disorders Chemically-Induced Disorders Methylphenidate Bupropion Methadone Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Antidepressive Agents, Second-Generation

2003 Clinical Trials

293. Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

Study ID Numbers: AK130934 First Posted: October 31, 2002 Last Update Posted: February 12, 2013 Last Verified: February 2013 Keywords provided by GlaxoSmithKline: ADD ADHD attention deficit hyperactivity Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System (...) to Brief Summary: This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention Deficit Disorder Drug: Extended-release bupropion hydrochloride Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 162 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double

2002 Clinical Trials

294. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. (Abstract)

Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. In the treatment of attention-deficit hyperactivity disorder (ADHD), the efficacy of the tricyclic antidepressants and monoamine oxidase inhibitor antidepressants has been compared with that of both placebo and the stimulants (methylphenidate and/or dextroamphetamine). However, the effectiveness of bupropion has been contrasted only with placebo. The primary aim of this study was to contrast (...) the efficacy of bupropion with that of methylphenidate in the treatment of ADHD.A double-blind, crossover design was used in this study. After a 14-day medication washout period, 15 ADHD subjects (7 to 17 years old) were randomized to either methylphenidate or bupropion for 6 weeks, washed out for an additional 2 weeks, and then "crossed over" to the other drug. Methylphenidate was titrated to the maximum effective dose of 0.4 to 1.3 mg/kg per day (mean 0.7 mg/kg per day) and bupropion was titrated

1995 Journal of the American Academy of Child and Adolescent Psychiatry Controlled trial quality: uncertain

295. Bupropion hydrochloride in attention deficit disorder with hyperactivity. (Abstract)

Bupropion hydrochloride in attention deficit disorder with hyperactivity. This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH).In a four-center, double-blind comparison of bupropion (n = 72) and placebo (n = 37), children aged 6 to 12 years meeting DSM-III criteria for ADDH were randomized to receive bupropion 3 to 6 mg/kg per day or placebo (...) were assessed weekly.A significant treatment effect, apparent as early as day 3, was present for both conduct problems and hyperactivity on the Conners 10-item and 39-item teacher's checklist, and at day 28 for conduct problems and restless-impulsive behavior on the 93-item parent questionnaire. Findings were of smaller magnitude for parent ratings than teacher ratings. Significant treatment effects were present on both the Continuous Performance Test and memory retrieval test. Effect sizes

1996 Journal of the American Academy of Child and Adolescent Psychiatry Controlled trial quality: predicted high

296. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. (Abstract)

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Despite the increasing recognition of attention deficit hyperactivity disorder (ADHD) in adults, there is a paucity of controlled pharmacological trials demonstrating the effectiveness of compounds used in treatment, particularly nonstimulants. The authors report results from a controlled investigation to determine the anti-ADHD efficacy of bupropion in adult patients with DSM-IV ADHD.This (...) was a double-blind, placebo-controlled, randomized, parallel, 6-week trial comparing patients receiving sustained-release bupropion (up to 200 mg b.i.d.) (N=21) to patients receiving placebo (N=19). The authors used standardized structured psychiatric instruments for diagnosis of ADHD. To measure improvement, they used separate assessments of ADHD, depression, and anxiety symptoms at baseline and each weekly visit.Of the 40 subjects (55% male) enrolled in the study, 38 completed the study. Bupropion

2001 American Journal of Psychiatry Controlled trial quality: uncertain

297. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. (Abstract)

Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Despite the increasing recognition of attention-deficit hyperactivity disorder (ADHD) in adults, there are few controlled trials demonstrating the effectiveness of pharmacological treatments, particularly with nonstimulants. One controlled trial found bupropion SR more effective than placebo in the treatment of ADHD adults. We conducted a controlled study to contrast the effectiveness (...) of bupropion SR and methylphenidate to placebo in ADHD adults. A randomized, double-blind, parallel design was used in this study. Following a 7-day placebo lead-in, 30 ADHD (DSM-IV) subjects (18-60 years old) were randomized to bupropion, methylphenidate, or placebo for 7 weeks. Methylphenidate was titrated over 1 week to a maximum dose of 0.9 mg/kg/d divided into 3 doses while bupropion was titrated over 2 weeks to a maximum dose of 200 mg A.M. and 100 mg P.M. Response rates based on Clinical Global

2001 Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>